Neuromuscular Disorders – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Neuromuscular Disorders – Drugs In Development, 2024 report and make more profitable business decisions.
Neuromuscular disorders are conditions that affect the function of the nerves and muscles in the body. They can cause muscle weakness, fatigue, pain, spasms, and other symptoms. Neuromuscular disorders can be inherited or acquired, and they can affect different parts of the neuromuscular system, such as the peripheral nerves, the skeletal muscles, or the neuromuscular junction. Some examples of neuromuscular disorders are amyotrophic lateral sclerosis (ALS), myasthenia gravis, muscular dystrophy, and Guillain-Barré syndrome. Neuromuscular disorders are diagnosed by clinical examination, electrodiagnostic studies, blood tests, genetic tests, and muscle biopsy. Treatment options depend on the type and severity of the disorder, and may include medication, surgery, physical therapy, occupational therapy, and supportive care. The outlook for people with neuromuscular disorders varies depending on the progression and complications of the disease.
The Neuromuscular Disorders drugs in development market research report provide comprehensive information on the therapeutics under development for Neuromuscular Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Neuromuscular Disorders and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Neuromuscular Disorders | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 49 molecules, with 47 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Neuromuscular Disorders therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Neuromuscular Disorders pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Neuromuscular Disorders treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Advertent Biotherapeutics IncAmplo Biotechnology Inc
Argenx SE
Ascidian Therapeutics Inc
Astellas Gene Therapies
Belief Biomed Inc
CANbridge Life Sciences Ltd
Chugai Pharmaceutical Co Ltd
Codiak BioSciences Inc
EditForce Inc
EG 427
GenKOre
Grit Science Biotechnology Co Ltd
Healx Ltd
Helixmith Co Ltd
Ildong Pharmaceutical Co Ltd
Ionis Pharmaceuticals Inc
Jiangsu Huatai Chenguang Pharmaceutical Co Ltd
Lee's Pharmaceutical Holdings Ltd
Neurophoenix
NMD Pharma AS
NYU Langone Health System
Pepgen Inc
PTC Therapeutics Inc
Reborna Biosciences Inc
Sarepta Therapeutics Inc
Skyhawk Therapeutics Inc
Socium Inc
StrideBio Inc
Takeda Pharmaceutical Co Ltd
University of Wisconsin Madison
Verge Genomics
Versameb AG
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Neuromuscular Disorders reports